Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Annals of the Rheumatic Diseases|March 11, 2014
Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?Elizabeth V Arkema, Jerker Jonsson, Eva Baecklund, et al.
Pharmacogenomics|February 7, 2020
<i>MTHFR</i>, <i>TYMS</i> and <i>SLCO1B1</i> polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritisJohanna Karlsson Sundbaum, Eva Baecklund, Niclas Eriksson, et al.
International Journal of Rheumatic Diseases|April 24, 2019
Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practiceJohanna Karlsson Sundbaum, Niclas Eriksson, Pär Hallberg, et al.
Acta Oncologica (Stockholm, Sweden)|April 1, 2021
Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disordersAmelie Kinch, Eva Baecklund, Daniel Molin, et al.
Arthritis and Rheumatism|April 11, 2003
Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relativesKarin Ekström, Henrik Hjalgrim, Lena Brandt, et al.
The Journal of Rheumatology|April 2, 2021
Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis CharacteristicsJohanna Karlsson Sundbaum, Elizabeth V Arkema, Judith Bruchfeld, et al.
British Journal of Haematology|June 10, 2021
Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in SwedenAndreea Sima, Peter Hollander, Eva Baecklund, et al.
Rheumatology (Oxford, England)|August 19, 2020
Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtypeKarin Hellgren, Daniela Di Giuseppe, Karin E Smedby, et al.
Annals of the Rheumatic Diseases|December 15, 2017
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologicsThomas Frisell, Eva Baecklund, Karin Bengtsson, et al.
Acta Oncologica (Stockholm, Sweden)|January 14, 2017
Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasingGunilla Enblad, Gustaf Martinsson, Eva Baecklund, et al.
Pageof 7